CELEX: 62016TN0802
Language: en
Date: 2016-11-08 00:00:00
Title: Case T-802/16: Action brought on 08 November 2016 — Endoceutics v EUIPO — Merck (FEMIBION)

23.1.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 22/45
            
         Action brought on 08 November 2016 — Endoceutics v EUIPO — Merck (FEMIBION)
   (Case T-802/16)
   (2017/C 022/61)
   Language in which the application was lodged: English
   
      Parties
   
   
      Applicant: Endoceutics, Inc. (Quebec, Canada) (represented by: M. Wahlin, lawyer)
   
      Defendant: European Union Intellectual Property Office (EUIPO)
   
      Other party to the proceedings before the Board of Appeal: Merck KGaA (Darmstadt, Germany)
   
      Details of the proceedings before EUIPO
   
   
      Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal
   
      Trade mark at issue: EU word mark ‘FEMIBION’ — EU trade mark No 898 924
   
      Procedure before EUIPO: Proceedings for a declaration of invalidity
   
      Contested decision: Decision of the First Board of Appeal of EUIPO of 14 July 2016 in Case R 1608/2015-1
   
      Form of order sought
   
   The applicant claims that the Court should:
   
               —
            
            
               annul the contested decision in part and revoke the EUTM for ‘pharmaceutical preparations for immune system support, for menopause, for menstruation, for treatment and management of pregnancy, for the prevention, treatment and management of stress, for the prevention, treatment and management of stress ill-balanced or deficient nutrition’;
            
         
               —
            
            
               order the EUTM proprietor to pay the Applicant’s costs on the appeal and with regard to the proceedings at the EUIPO.
            
         
      Plea in law
   
   
               —
            
            
               Infringement of Article 51(1)(a) of Regulation No 207/2009.